| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10044531 | HBV | ENSG00000126934.15 | protein_coding | MAP2K2 | Yes | No | 5605 | P36507 |
| TVIS30004704 | HIV | ENSG00000126934.15 | protein_coding | MAP2K2 | Yes | No | 5605 | P36507 |
| TVIS30012505 | HIV | ENSG00000126934.15 | protein_coding | MAP2K2 | Yes | No | 5605 | P36507 |
| TVIS30047381 | HIV | ENSG00000126934.15 | protein_coding | MAP2K2 | Yes | No | 5605 | P36507 |
| TVIS30047382 | HIV | ENSG00000126934.15 | protein_coding | MAP2K2 | Yes | No | 5605 | P36507 |
| TVIS30047383 | HIV | ENSG00000126934.15 | protein_coding | MAP2K2 | Yes | No | 5605 | P36507 |
| TVIS30047384 | HIV | ENSG00000126934.15 | protein_coding | MAP2K2 | Yes | No | 5605 | P36507 |
| TVIS30047385 | HIV | ENSG00000126934.15 | protein_coding | MAP2K2 | Yes | No | 5605 | P36507 |
| TVIS30047386 | HIV | ENSG00000126934.15 | protein_coding | MAP2K2 | Yes | No | 5605 | P36507 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | MAP2K2 |
|---|---|
| DrugBank ID | DB11689 |
| Drug Name | Selumetinib |
| Target ID | BE0004744 |
| UniProt ID | P36507 |
| Regulation Type | inhibitor |
| PubMed IDs | 17332304; 17699718; 28029918 |
| Citations | Yeh TC, Marsh V, Bernat BA, Ballard J, Colwell H, Evans RJ, Parry J, Smith D, Brandhuber BJ, Gross S, Marlow A, Hurley B, Lyssikatos J, Lee PA, Winkler JD, Koch K, Wallace E: Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin Cancer Res. 2007 Mar 1;13(5):1576-83. doi: 10.1158/1078-0432.CCR-06-1150.@@Davies BR, Logie A, McKay JS, Martin P, Steele S, Jenkins R, Cockerill M, Cartlidge S, Smith PD: AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models. Mol Cancer Ther. 2007 Aug;6(8):2209-19. doi: 10.1158/1535-7163.MCT-07-0231.@@Dombi E, Baldwin A, Marcus LJ, Fisher MJ, Weiss B, Kim A, Whitcomb P, Martin S, Aschbacher-Smith LE, Rizvi TA, Wu J, Ershler R, Wolters P, Therrien J, Glod J, Belasco JB, Schorry E, Brofferio A, Starosta AJ, Gillespie A, Doyle AL, Ratner N, Widemann BC: Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas. N Engl J Med. 2016 Dec 29;375(26):2550-2560. doi: 10.1056/NEJMoa1605943. |
| Groups | Approved; Investigational |
| Direct Classification | Benzimidazoles |
| SMILES | CN1C=NC2=C(F)C(NC3=C(Cl)C=C(Br)C=C3)=C(C=C12)C(=O)NOCCO |
| Pathways | |
| PharmGKB | PA166129529 |
| ChEMBL | CHEMBL1614701 |
